Form 6-K GLAXOSMITHKLINE PLC For: Oct 27
FORM 6-K
�
�
SECURITIES AND EXCHANGE COMMISSION(
Washington D.C. 20549
�
�
Report of Foreign Issuer
�
�
Pursuant to Rule 13a-16 or 15d-16 of(
the Securities Exchange Act of 1934
�
�
�
For period ending�October 2014
�
GlaxoSmithKline plc
(Name of registrant)(
�
�
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)(
�
�
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F(
�
�
Form 20-F x��� �Form 40-F(
�
--(
�
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.(
�
�
Yes����� No x
--
�
�
Publication of Supplementary Prospectus
�
The following Supplementary Prospectus dated 27 October 2014, supplementing the Base Prospectus dated 4 August 2014, has been approved by the UK Listing Authority and is available for viewing:
�
GlaxoSmithKline plc and GlaxoSmithKline Capital plc
�15,000,000,000 Euro Medium Term Note Programme
�
Copies of the Supplementary Prospectus and the documents incorporated by reference therein have been submitted to the National Storage Mechanism and will shortly be available for inspection at:
�
�
http://www.morningstar.co.uk/uk/NSM
.
�
The Supplementary Prospectus will also be available for viewing at:
�
http://www.gsk.com/en-gb/investors/stock-exchange-announcements/
�
For further information, please contact:
�
GlaxoSmithKline plc
�
980 Great West Road
�
Brentford
�
Middlesex
�
TW8 9GS
�
United Kingdom
�
�
�
Enquiries:
�
UK Media enquiries:
|
David Mawdsley
Simon Steel
|
(020) 8047 5502
(020) 8047 5502
�
|
European Analyst/Investor enquiries:
|
Gary Davies
Ziba Shamsi
|
�(020) 8047 5503
�(020) 8047 5543
|
BASIS ON WHICH YOU MAY ACCESS THE SUPPLEMENTARY PROSPECTUS AND BASE PROSPECTUS
�
Please note that the information contained in the Supplementary Prospectus and the Base Prospectus may be
addressed to and/or targeted at persons who are residents of particular
countries (specified in the Base Prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to
whom the offer contained in the Base Prospectus is not addressed. Prior to relying
on the information contained in the Base Prospectus you must ascertain from the Base P
rospectus whether or not you are part of the intended addressees of the
information contained therein.
Your right to access this service is conditional upon complying with the above requirements.
�
�
�
�
�
�
�
�
SIGNATURES
�
�
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.(
�
�
GlaxoSmithKline plc
(Registrant)(
Date:�October 27,�2014�
�
�
By:�VICTORIA WHYTE
----------------------
�
�
Victoria�Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Amex to Consolidate Team Zone with 210 and E3 Gold Zones to Form a 1.4 km Mineralized Corridor and Announces Further Drill Results
- Silicon Labs Reports First Quarter 2024 Results
- CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!